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Summary
Background Oesophageal cancer is a common and often fatal cancer that has two main histological subtypes: 
oesophageal squamous cell carcinoma and oesophageal adenocarcinoma. Updated statistics on the incidence and 
mortality of oesophageal cancer, and on the disability-adjusted life-years (DALYs) caused by the disease, can assist 
policy makers in allocating resources for prevention, treatment, and care of oesophageal cancer. We report the latest 
estimates of these statistics for 195 countries and territories between 1990 and 2017, by age, sex, and Socio-demographic 
Index (SDI), using data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD).
Methods We used data from vital registration systems, vital registration-samples, verbal autopsy records, and cancer 
registries, combined with relevant modelling, to estimate the mortality, incidence, and burden of oesophageal cancer 
from 1990 to 2017. Mortality-to-incidence ratios (MIRs) were estimated and fed into a Cause of Death Ensemble 
model (CODEm) including risk factors. MIRs were used for mortality and non-fatal modelling. Estimates of DALYs 
attributable to the main risk factors of oesophageal cancer available in GBD were also calculated. The proportion of 
oesophageal squamous cell carcinoma to all oesophageal cancers was extracted by use of publicly available data, and 
its variation was examined against SDI, the Healthcare Access and Quality (HAQ) Index, and available risk factors in 
GBD that are specific for oesophageal squamous cell carcinoma (eg, unimproved water source and indoor air 
pollution) and for oesophageal adenocarcinoma (gastro-oesophageal reflux disease).
Findings There were 473 000 (95% uncertainty interval [95% UI] 459 000–485 000) new cases of oesophageal cancer 
and 436 000 (425 000–448 000) deaths due to oesophageal cancer in 2017. Age-standardised incidence was 5·9 (5·7–6·1) 
per 100 000 population and age-standardised mortality was 5·5 (5·3–5·6) per 100 000. Oesophageal cancer caused 
9·78 million (9·53–10·03) DALYs, with an age-standardised rate of 120 (117–123) per 100 000 population. Between 
1990 and 2017, age-standardised incidence decreased by 22·0% (18·6–25·2), mortality decreased by 29·0% 
(25·8–32·0), and DALYs decreased by 33·4% (30·4–36·1) globally. However, as a result of population growth and 
ageing, the total number of new cases increased by 52·3% (45·9–58·9), from 310 000 (300 000–322 000) to 473 000 
(459 000–485 000); the number of deaths increased by 40·0% (34·1–46·3), from 311 000 (301 000–323 000) to 436 000 
(425 000–448 000); and total DALYs increased by 27·4% (22·1–33·1), from 7·68 million (7·42–7·97) to 9·78 million 
(9·53–10·03). At the national level, China had the highest number of incident cases (235 000 [223 000–246 000]), 
deaths (213 000 [203 000–223 000]), and DALYs (4·46 million [4·25–4·69]) in 2017. The highest national-level age-
standardised incidence rates in 2017 were observed in Malawi (23·0 [19·4–26·5] per 100 000 population) and Mongolia 
(18·5 [16·4–20·8] per 100 000). In 2017, age-standardised incidence was 2·7 times higher, mortality 2·9 times higher, 
and DALYs 3·0 times higher in males than in females. In 2017, a substantial proportion of oesophageal cancer DALYs 
were attributable to known risk factors: tobacco smoking (39·0% [35·5–42·2]), alcohol consumption (33·8% 
[27·3–39·9]), high BMI (19·5% [6·3–36·0]), a diet low in fruits (19·1% [4·2–34·6]), and use of chewing tobacco 
(7·5% [5·2–9·6]). Countries with a low SDI and HAQ Index and high levels of indoor air pollution had a higher 
proportion of oesophageal squamous cell carcinoma to all oesophageal cancer cases than did countries with a high 
SDI and HAQ Index and with low levels of indoor air pollution. 
Interpretation Despite reductions in age-standardised incidence and mortality rates, oesophageal cancer remains a 
major cause of cancer mortality and burden across the world. Oesophageal cancer is a highly fatal disease, requiring 
increased primary prevention efforts and, possibly, screening in some high-risk areas. Substantial variation exists in 
age-standardised incidence rates across regions and countries, for reasons that are unclear. 
Funding Bill & Melinda Gates Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license. 
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Introduction
Oesophageal cancer is one of the leading causes of 
cancer mortality worldwide.1–3 Together with other forms 
of gastrointestinal cancers, such as stomach cancer, 
colorectal cancer, pancreatic cancer, and hepatocellular 
carcinoma, oesophageal cancer causes approximately a 
third of all disability-adjusted life-years (DALYs) due to 
cancer.1,3
Previous publications have reported on various health 
metrics of oesophageal cancer, including its incidence, 
mortality, and DALY rates, as well as its risk factors.3 
Some of these studies have presented comprehensive 
global data for all cancers combined and more sparse 
data for each individual cancer.1–3 Others have provided 
more detailed data about oesophageal cancer for a certain 
country or region,4,5 or used global data that were several 
years old and did not have information about DALYs.6,7 
We provide, to the best of our knowledge, the first set of 
updated estimates about a wide range of oesophageal 
cancer health measures at global, regional, and country-
specific levels for 195 countries and territories.
There are two main histological subtypes of oesophageal 
cancer: oesophageal adenocarcinoma (which is linked to 
obesity, smoking, and gastro-oesophageal reflux disease) 
and oesophageal squamous cell carcinoma (which is 
linked to alcohol and tobacco consumption). Although 
several high-risk regions for oesophageal squamous cell 
carcinoma are adjacent to regions with medium or low 
risk, such a pattern has not been observed for oesophageal 
adenocarcinoma. Globally, more than 85% of all incident 
oesophageal cancer cases are oesophageal squamous cell 
carcinoma.8
In this analysis of data from the Global Burden of 
Diseases, Injuries, and Risk Factors Study (GBD) 2017, we 
present estimates of the number of incident cases and 
deaths, as well as age-standardised incidence, mortality, 
and DALY rates for oesophageal cancer from 1990 to 2017, 
by age and sex, for 195 countries and territories. 
Furthermore, we provide age-standardised DALYs by 
Socio-demographic Index (SDI). Finally, we provide 
estimates of the proportion of DALYs attributable to 
several major oesophageal cancer risk factors, including 
tobacco smoking and chewing, alcohol consumption, low 
intake of fruits, and high body-mass index (BMI). Through 
this comprehensive evaluation of global oesophageal 
cancer measures, we hope to provide additional infor-
mation for policy makers, funding agencies, and 
researchers, so they can develop strategies to help prevent 
and treat oesophageal cancer in high-risk locations, 
determine allocation of scarce health resources, and guide 
the direction of future research on oesophageal cancer.
Methods
Overview
This study is part of GBD 2017, which includes estimates 
for 195 countries and territories, 21 regions, and 
Research in context
Evidence before this study
Oesophageal cancer is one of the leading causes of cancer 
mortality worldwide. Previous publications have reported on 
various health metrics of oesophageal cancer, but to our 
knowledge, no study has provided detailed estimates of 
incidence, mortality, disability-adjusted life-years (DALYs), and 
DALYs attributable to major risk factors for 195 countries and 
territories around the world. Furthermore, previous studies 
have not investigated the country-level correlation between 
the proportion of new oesophageal squamous cell carcinoma to 
all oesophageal cancer cases and potential risk factors for 
oesophageal squamous cell carcinoma, such as indoor air 
pollution and inadequate access to improved water sources.
Added value of this study
We used data from the Global Burden of Diseases, Injuries, and 
Risk Factors Study (GBD) 2017 to provide the most up-to-date 
estimates on a wide range of health measures related to 
oesophageal cancer at global, regional, and country-specific 
levels for 195 countries and territories, and by sex, age group, 
and Socio-demographic Index (SDI). We present estimated 
numbers and age-standardised incidence rates for oesophageal 
cancer in 2017, as well as trends from 1990 to 2017. We also 
describe DALYs attributed to several major risk factors for 
oesophageal cancer. Furthermore, for the first time, we present 
the correlation of the country-level proportion of new 
oesophageal squamous cell carcinoma to all oesophageal 
cancer cases with several potential risk factors for oesophageal 
squamous cell carcinoma, including indoor air pollution, 
inadequate access to improved water sources, and SDI. These 
correlations can guide further investigations into the causes of 
oesophageal squamous cell carcinoma.
Implications of all the available evidence
Oesophageal cancer remains a major cause of cancer mortality 
and disease burden across the world, requiring substantial 
preventive measures and possibly screening by use of upper 
gastrointestinal endoscopy in certain high-risk countries. 
The highest burden of oesophageal cancer (in terms of the 
number of DALYs) is in east Asia, particularly China, where 
screening has been shown to be effective in increasing survival 
rates. Other high-incidence regions are in central Asia and 
sub-Saharan Africa. The main reasons for these high rates are 
unknown. Further research into the causes of oesophageal 
cancer in these high-risk areas is warranted. Our findings are 
consistent with previous studies that suggest indoor air 
pollution, inadequate access to improved water sources, and 
low socioeconomic status are associated with increased risk of 
oesophageal squamous cell carcinoma. Several epidemiological 
studies are ongoing by different research groups, and we expect 
to see new findings over the next few years.
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seven super-regions. GBD 2017 presented estimates for 
359 diseases and injuries; 282 causes of death; and 
84 behavioural, environmental, occupational, and 
metabolic risk factors. The methodology used to collect 
data for this research has been discussed previously.9–12 
Rates per 100 000 population were age-standardised 
according to the GBD world population.13 95% uncertainty 
intervals (95% UIs) were reported for estimates, including 
for sources of uncertainty arising from measurement 
error, potential biases, and modelling. Statistical analyses 
were done with Python (version 2.7.14), R (version 3.3.2), 
and Stata (release 15) software. This study is compliant 
with the Guidelines for Accurate and Transparent Health 
Estimates Reporting (GATHER) statement.
Data and estimation framework
Data came from vital registration systems (19 323 site-
years), vital registration-samples (793 site-years), verbal 
autopsy records (419 site-years), and cancer registries 
(5497 site-years).9 Of these, only cancer registries had 
both mortality and incidence data, whereas vital registries 
and verbal autopsies had only mortality data. By use of 
International Classification of Diseases 10 (ICD-10) 
codes,10 all cancers coded as C15.0-C15.9, D00.1, and 
D13.0 were considered to be oesophageal cancer. Four 
sequelae and associated disability weights were used, 
including diagnosis, controlled, metastatic, and terminal 
phases (appendix p 9).10 Disability weights ranged from 
0 (perfect health) to 1 (equivalent to death).
Mortality modelling
Some locations had high-quality incidence and mortality 
cancer registry data, whereas data were sparse in other 
locations.9 Therefore, incidence and mortality estimates 
were obtained with a combination of available data and 
modelling. We first estimated mortality-to-incidence 
ratios (MIRs) using sources that had accurate incidence 
and mortality data for the same year. MIRs were estimated 
for other locations by use of a linear-step mixed-effects 
model with logit link functions, with the Healthcare 
Access and Quality (HAQ) Index, age, and sex as 
covariates. The resulting estimates were then smoothed 
over space and time and adjusted with spatiotemporal 
Gaussian process regression.14 Estimated mortality data 
for each site were obtained by multiplying incidence data 
by MIRs. As the next step, both observed and estimated 
mortality data were fed into a Cause of Death Ensemble 
model (CODEm), along with the mortality data from vital 
registration and verbal autopsy.9 The covariates included 
in CODEm that were assumed to have a positive 
relationship with oesophageal cancer mortality were 
smoking prevalence, tobacco consumption (cigarettes per 
capita), mean BMI, log-transformed age-standardised 
summary exposure value scalar for oesophageal cancer, 
alcohol (L per person), and indoor air pollution 
(prevalence of households cooking with coal or biomass). 
The covariates included in the CODEm that were 
assumed to have a negative relationship with oesophageal 
cancer were fruit intake, adjusted (g); improved water 
source (proportion with access); HAQ Index; vegetable 
intake, adjusted (g); sanitation (proportion with access); 
and education (years per person). Finally, the covariates 
included in the CODEm that had no prior assumptions 
about the direction of the relationship were lag-distributed 
income (international dollar [Int$] per person) and SDI. 
All the covariates had a plausible association with 
oesophageal cancer deaths based on the published 
literature, although evidence of causality was not required 
for their inclusion in the model.12,15
Non-fatal modelling
The final mortality estimates were obtained from 
CoDCorrect,9 with modelling described above, and were 
divided by the MIR to compute oesophageal cancer 
incidence. The prevalence of oesophageal cancer was 
calculated by modelling survival for each incidence cohort 
by using the MIR as a scalar and adjusting for expected 
background mortality.10 The cohort members who had 
survived more than 10 years were assumed to be cured, 
and these cases were divided into two sequelae: the 
diagnosis and primary therapy phase and the controlled 
phase. Furthermore, the prevalence for the cohort that 
died during the 10-year period was categorised into four 
sequelae (appendix p 9). A time duration of 5 months was 
used to define the diagnosis and primary therapy phase,16 
4·6 months used to define the metastatic phase,17 and 
1 month used to define the terminal phase. The remaining 
time was assigned to the controlled phase.
Following this process, each sequela-specific prevalence 
rate was multiplied by a sequela-specific disability weight 
to estimate the sequelae-specific years lived with disability 
(YLDs). DALYs were calculated as the sum years of life 
lost (YLLs) due to premature death and YLDs.
Socio-demographic Index (SDI)
SDI was used in this study to determine the relationship of 
a country’s socioeconomic development status with age-
standardised incidence and mortality rates for oesophageal 
cancer. In GBD 2017, SDI was revised to better reflect the 
development status of each country.9–11 SDI ranges from 
0 (worst) to 1 (best) and is composed of the total fertility 
rate under the age of 25 years, mean education for those 
aged 15 years and older, and lag-distributed income per 
capita.13 The HAQ Index determines the personal access to 
and quality of health care for 195 countries and territories 
and is calculated on the basis of amenable mortality, or 
deaths from causes that should not occur in the presence 
of effective medical care. The HAQ Index ranges from 
0 (worst) to 100 (best). More details about the HAQ Index 
are presented in previous publications.18
Risk factors
We calculated and reported the percentage of DALYs due 
to oesophageal cancer that were attributable to smoking, 
See Online for appendix
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alcohol use, high BMI, a diet low in fruits, and chewing 
tobacco (established oesophageal cancer risk factors with 
available data in GBD). Details about the definitions of 
these risk factors and their relative risk for oesophageal 
cancer are described elsewhere.12
Publicly available data for the two main histological 
subtypes of oesophageal cancer (ie, oesophageal 
squamous cell carcinoma and oesophageal adeno-
carcinoma) were obtained from Cancer Incidence in Five 
Continents (Vol XI).7 Local cancer registries from 
151 countries provided data about the incidence of 
oesophageal squamous cell carcinoma, oesophageal 
adenocarcinoma, and all oesophageal cancer. The 
proportion of the incidence of oesophageal squamous cell 
carcinoma out of all oesophageal cancer cases was 
calculated for each country and territory and linked to 
GBD estimates using country codes. We regressed the 
proportion of oesophageal squamous cell carcinoma to all 
oesophageal cancer cases (as a continuous response 
variable) against SDI and the HAQ Index, and against risk 
factors for oesophageal squamous cell carcinoma 
(percentage of the population with access to improved 
water sources, and prevalence of households cooking with 
coal or biomass [indoor air pollution]) and oesophageal 
adenocarcinoma (gastro-oesophageal reflux disease).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or the 
writing of the report. All authors had full access to the 
data in the study and had final responsibility for the 
decision to submit for publication.
Results
In 2017, there were 473 000 (95% UI 459 000–485 000) new 
cases of oesophageal cancer and 436 000 (425 000–448 000) 
deaths due to oesophageal cancer. Age-standardised 
incidence was 5·9 (5·7–6·1) per 100 000 population and 
the age-standardised mortality rate was 5·5 (5·3–5·6) per 
100 000 population. 9·78 million (9·53–10·03) DALYs 
were due to oesophageal cancer, with an age-standardised 
rate of 119·9 (116·9–123·0) per 100 000 population 
(appendix pp 10–33).
Between 1990 and 2017, global age-standardised 
incidence decreased by 22·0% (95% UI 18·6–25·2), 
mortality decreased by 29·0% (25·8–32·0), and DALYs 
decreased by 33·4% (30·4–36·1; appendix pp 10–33). 
However, during the same period, the total number of 
new cases increased by 52·3% (45·9–58·9), from 310 000 
(301 000–322 000) to 473 000 (459 000–485 000); the 
number of deaths increased by 40·0% (34·1–46·3), from 
311 000 (301 000–323 000) to 436 000 (425 000–448 000); 
and total DALYs increased by 27·4% (22·1–33·1), from 
7·68 million (7·42–7·97) to 9·78 million (9·53–10·03; 
appendix pp 2, 10–33).
From among 21 GBD regions, in 2017, the highest 
age-standardised incidence rates were in east Asia 
(12·1 [95% UI 11·5–12·7] per 100 000 population), 
southern sub-Saharan Africa (10·0 [9·5–10·4] per 
100 000 population), eastern sub-Saharan Africa 
(7·8 [7·2–8·6] per 100 000 population), central sub-
Saharan Africa (7·3 [6·2–8·5] per 100 000 population), 
and central Asia (5·7 [5·4–5·9]; figure 1A, appendix 
pp 10–17). In 2017, the highest regional age-standardised 
incidence rate (12·1 per 100 000 population in east Asia) 
was 9·3 times higher than the lowest (1·3 [1·2–1·4] per 
100 000 population in Andean Latin America; appendix 
pp 10–17). With some minor change in rank order, 
regions with high age-standardised incidence rates also 
Figure 1: The age-standardised incidence (A) and death rates (B) of oesophageal cancer in 2017 for 21 GBD 
regions, by sex
GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
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Figure 2: Age-standardised incidence (A) and death rates (B) of oesophageal cancer per 100 000 population in 2017, by country and territory
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and Tobago. Isl=Islands. FSM=Federated States of Micronesia. TLS=Timor-Leste.
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had the highest age-standardised mortality and DALY 
rates (figure 1B, appendix pp 18–33). Because of the 
high incidence rates and its large population, over half 
of all new cases of oesophageal cancer in 2017 came 
from east Asia (245 000 [233 000–256 000] of 473 000 
[459 000–485 000] global incident cases; 51·8%; 
appendix pp 10–17). By contrast, the lowest age-
standardised incidence, mortality, and DALY rates were 
seen in Andean Latin America, central Latin America, 
Oceania, north Africa and the Middle East, and 
southeast Asia (figure 1, appendix pp 10–33).
Stark differences were observed in age-standardised 
incidence rates of oesophageal cancer between nearby 
regions. For example, the age-standardised incidence 
rate in southeast Asia, which is close to east Asia, was 
low (2·5 [95% UI 2·4–2·7] per 100 000 population in 
2017). Similarly, in contrast to the high age-standardised 
incidence rate seen in east sub-Saharan Africa 
(7·8 [7·2–8·6] per 100 000 population in 2017), the age-
adjusted incidence rate in western sub-Saharan Africa 
was low (4·0 [3·5–4·7] per 100 000 population in 2017).
Between 1990 and 2017, the regional age-standardised 
incidence, mortality, and DALY rates for oesophageal 
cancer decreased in all GBD regions except for high-
income North America for age-standardised incidence 
rates (7·4% [95% UI 3·9–11·1]), and western sub-Saharan 
Africa for all three measures (percentage change 35·7% 
[15·6–58·9] for age-standardised incidence, 37·2% 
[17·1–60·3] for age-standardised mortality, and 31·4% 
[12·3–55·4] for age-standardised DALYs; appendix pp 3–4, 
10–33). The sharpest declines in age-standardised 
incidence rates over the study period were seen in central 
Asia (55·1% [95% UI 52·5–57·5]), east Asia (36·1% 
[31·3–40·9]), southern Latin America (40·9% [34·8–45·7]), 
Andean Latin America (33·5% [26·5–40·4]), central Latin 
America (32·8% [29·6–36·0]), central sub-Saharan Africa 
(30·1% [18·5–41·2]), and eastern sub-Saharan Africa 
(27·4% [19·0–34·7]).
At the national level, China had the highest number of 
incident cases (235 000 [95% UI 223 000–246 000]), deaths 
(213 000 [203 000–223 000]), and DALYs (4·46 million 
[4·25–4·69]) in 2017, comprising nearly half of new cases, 
deaths, and DALYs globally that year. The highest 
estimated national-level age-standardised incidence, 
mortality, and DALY rates in 2017 were observed in certain 
countries in sub-Saharan Africa (eg, Malawi, eSwatini, 
Lesotho, Zimbabwe, and Uganda), central Asia (eg, 
Mongolia, Turkmenistan, and Azerbaijan), and east Asia 
(eg, China; figure 2; appendix pp 10–33). Malawi had the 
highest age-standardised incidence rate (23·0 [19·4–26·5] 
per 100 000 population), followed by Mongolia (18·5 
(16·4–20·8) per 100 000 population). In 2017, the ratio of 
the highest age-standardised incidence rate to the lowest 
(0·6 [0·6–0·7] per 100 000 population in Iraq) was 1. 
Patterns of age-standardised mortality and DALY rates 
closely followed those of age-standardised incidence 
rates, which reflects the poor survival of patients with 
oesophageal cancer, particularly in low-income and 
middle-income countries.
Similar to the global and regional trends, between 
1990 and 2017, most countries and territories had a 
decrease in age-standardised incidence, mortality, and 
DALY rates due to oesophageal cancer (appendix 
pp 10–33). For example, age-standardised incidence rates 
decreased in Turkmenistan (by 71·9% [95% UI 
69·1 to 74·6]), Uzbekistan (by 68·1% [64·1 to 71·7]), 
Kazakhstan (by 64·3% [61·4 to 67·2]), Kyrgyzstan (by 
55·4% [51·1 to 59·3]), and China (by 36·9% [32·1 to 41·7]). 
However, there were clear exceptions to the overall trend, 
Figure 3: Global number and age-standardised rates of incidence (A), mortality (B), and DALYs (C) of 
oesophageal cancer per 100 000 population by age and sex, 2017
Shading indicates the upper and lower limits of the 95% uncertainty intervals (95% UIs). DALY=disability-adjusted 
life-year.
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particularly among high-income countries. For example, 
age-standardised incidence rates increased in the USA 
(6·7% [95% UI 3·1 to 10·4]), Canada (10·6% 
[–0·4 to 23·5]), Austria (23·1% [9·9 to 38·4]), Germany 
(38·4% [19·9 to 60·2]), Latvia (53·3% [28·0 to 81·4]), and 
the Netherlands (86·6% [68·2 to 106·6]). Likewise, some 
countries in western sub-Saharan Africa, such as Sierra 
Leone (61·4% [23·9 to 109·9]), Benin (74·6% 
[38·9 to 124·2]), and Chad (84·1% [46·4 to 128·9]), had 
increased age-standardised incidence rates. Incidence, 
mortality, and DALY rates varied by age, sex, and SDI in 
2017. Incidence and mortality rates started climbing at age 
50 years but DALYs started climbing at age 40 years and 
dropped in the oldest age groups, as younger age groups 
lost more years of life (figure 3). Incidence, mortality, and 
DALY rates were also higher in males than in females in 
all age groups (figure 3). Age-standardised incidence rates 
were 2·7 times higher, mortality rates 2·9 times higher, 
and DALY rates 3·0 times higher in males than in females 
(appendix pp 10–33). Because oesophageal cancer is a 
highly fatal disease with a high MIR (0·91), almost all 
DALYs (98·7%) were attributable to YLLs due to 
premature death (appendix p 5). The observed regional 
and national age-standardised DALY rates in relation to 
SDI, versus the expected level for each location on the 
basis of SDI, are shown in figure 4. The high-income 
regions, central and eastern Europe, and tropical and 
southern Latin America closely followed expected trends 
over the study period. Among many of the middle SDI 
regions, however, the observed patterns varied widely, 
with some regions staying well below expected levels 
throughout the study period with little change in age-
standardised rates and others well above expected levels 
but with fluctuating or decreasing age-standardised rates 
Figure 4: Age-standardised DALY rates for oesophageal cancer for 21 GBD regions (A) and 195 countries and territories (B) by Socio-demographic Index, 
1990–2017
Expected values based on Socio-demographic Index and disease rates in all locations are shown as the black line. DALY=disability-adjusted life-year. GBD=Global 
Burden of Diseases, Injuries, and Risk Factors Study.
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(figure 4A). In 2017, there was an inverse association 
between age-standardised DALY rates for oesophageal 
cancer and SDI at the national level, with some exceptions 
(figure 4B). Similar patterns were observed for incidence 
and mortality in relation ship to SDI (appendix p 6).
At the global level, a substantial proportion of DALYs 
were attributable to the five risk factors for which GBD 
estimates were available, including 39·0% (95% UI 
35·5–42·2) attributable to tobacco smoking, 33·8% 
(27·3–39·9) to alcohol consumption, 19·5% (6·3–36·0) 
to high BMI, 19·1% (4·2–34·6) to a diet low in fruits, and 
7·5% (5·2–9·6) to use of chewing tobacco (figure 5). The 
impact of these risk factors varied by region. For example, 
the impact of smoking was highest in eastern Europe 
(53·7% of DALYs were attributable to smoking) and 
central Europe (49·8%), where smoking is still prevalent, 
and lowest in western sub-Saharan Africa (14·8%). 
Likewise, the impact of alcohol consumption was highest 
in central Europe (55·8% of DALYs attributable to 
alcohol) and eastern Europe (54·3%), and lowest in north 
Africa and the Middle East (7·2%), where alcohol 
consumption is relatively low.
Clear patterns emerged by generating graphs of the 
proportion of oesophageal squamous cell carcinoma to 
oesophageal adenocarcinoma cases and to all oesophageal 
cancer cases versus SDI, HAQ Index, and household air 
pollution, which were obtained by linking to data from 
Cancer Incidence in Five Continents (Vol XI; appendix 
pp 7, 34–37). At the country level, this proportion was 
strongly positively correlated with indoor air pollution, 
even after adjustment for SDI, meaning that countries 
and territories with worse indoor air pollution had higher 
proportions of oesophageal squamous cell carcinoma 
from among all oesophageal cancer cases. The proportion 
of oesophageal squamous cell carcinoma to all oesophageal 
cancer cases was also positively correlated with inadequate 
access to improved water sources, but the strength of this 
correlation decreased after adjusting for SDI. A higher 
proportion of oesophageal squamous cell carcinoma to all 
oesophageal cancer cases was inversely correlated with 
SDI and the HAQ Index, meaning that countries and 
territories higher on the SDI and HAQ Indexes had lower 
proportions of oesophageal squamous cell carcinoma 
from among all oesophageal cancer cases. No clear pattern 
was observed for the association between the proportion 
of oesophageal squamous cell carcinoma to all oesophageal 
cancer cases versus the prevalence of gastro-oesophageal 
reflux disease (appendix p 8).
Discussion
The results of GBD 2017 show that the large variations 
in age-standardised incidence, mortality, and DALY 
Figure 5: Proportion of oesophageal cancer DALYs attributable to tobacco smoking and chewing, alcohol use, high BMI, and low intake of fruits, for 21 GBD regions, 2017
BMI=body-mass index. DALY=disability-adjusted life-year. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
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rates across countries and territories are still a main 
epidemiological feature of oesophageal cancer (with the 
majority of cases being oesophageal squamous cell 
carcinoma), indicating the importance of finer 
delineation of hotspots to specify at-risk populations. 
GBD estimates show a decrease in age-adjusted 
incidence rates in most parts of the world, particularly 
in regions where oesophageal squamous cell carcinoma 
is the dominant histological subtype (eg, in central 
Asia), but an increase in these rates in regions where 
oesophageal adeno carcinoma is the major subtype 
(eg, high-income North America), emphasising the 
importance of collecting data to differentiate these 
two subtypes. Further investigation is needed of the 
causes of the high age-standardised incidence rates 
seen in some parts of the world, particularly in high-risk 
areas of sub-Saharan Africa, Mongolia, China, and Iran. 
The observed global decrease in age-standardised 
incidence rate from 1990 to 2017 is perhaps due to 
improvements in several social and environmental 
factors, such as the SDI.
Our findings add to the literature by providing the most 
up-to-date data on a wide range of oesophageal cancer 
health metrics, including age-standardised rates of DALYs 
for 195 countries and territories, DALYs attributable to 
several major risk factors of oesophageal cancer, and 
trends of these measures from 1990 to 2017. Although 
age-standardised incidence and mortality rates of 
oesophageal cancer have decreased at the global level over 
the past three decades, absolute numbers of new 
oesophageal cancer cases and deaths and DALYs 
attributable to oesophageal cancer have increased as a 
result of population growth and ageing. These trends 
over time indicate that oesophageal cancer still causes a 
substantial disease burden across the world, and the 
overall burden could continue to rise. Our results 
corroborate findings from previous studies but use 
different sources of data and estimation methods. The 
country-level positive correlations between the proportion 
of oesophageal squamous cell carcinoma to all 
oesophageal cancer cases and high indoor pollution, low 
access to improved water sources, low SDI, and low HAQ 
Index are novel and support the hypothesis that these 
factors could contribute to the risk of oesophageal 
squamous cell carcinoma. Gastro-oesophageal reflux 
disease, an established risk factor for oesophageal 
adenocarcinoma (but not oesophageal squamous cell 
carcinoma), showed a U-shaped relationship with the 
proportion of oesophageal squamous cell carcinoma to all 
oesophageal cancer cases. No clear explanation exists for 
this unexpected finding, although we can suggest some 
hypotheses. This U-shaped relationship was primarily 
due to aberrations seen in eastern Europe, an area that is 
close to geographical areas of Asia where oesophageal 
squamous cell carcinoma is prevalent, and adjacent to 
western Europe, where gastro-oesophageal reflux disease 
and oesophageal adenocarcinoma are highly prevalent. 
This geographical proximity, combined with spatial 
modelling, might have affected the estimates. Another 
possibility is a potential association between gastro-
oesophageal reflux disease prevalence and one or more 
oesophageal squamous cell carcinoma risk factors in 
these regions.
The estimated numbers of new cases of oesophageal 
cancer based on GBD estimates were lower than those 
estimated with the 2018 Global Cancer Observatory 
(GLOBOCAN).2 We estimated 473 000 new cases and 
436 000 deaths in 2017 using GBD, versus 572 000 new 
cases and 509 000 deaths in GLOBOCAN data. These 
discrepancies are due to incomplete data in both datasets 
and differences in modelling. For example, weighting 
the data by the level of their completeness in GBD might 
give more weight to data from high-income countries, 
where data are more complete and oesophageal cancer 
incidence rates are low.
Some countries in east and central Asia, as well as in 
eastern, central, and southern sub-Saharan Africa, had 
high age-standardised incidence, mortality, and DALY 
rates over the study period. These findings are consistent 
with previous literature. Since at least the early 1970s, 
vast areas of Asia, extending from China and Mongolia to 
the Caspian Sea, have been known to have high rates of 
oesophageal cancer.19 This area, dubbed the so-called 
Asian oesophageal cancer belt,19–21 was along the path of 
the Silk Road, which has led to hypotheses that some 
shared environmental risk or genes passed along this 
route were the common causes of the observed high 
risks.19,21,22 More than 90% of oesophageal cancer cases in 
this part of the world are of the squamous cell type 
(oesophageal squamous cell carcinoma).22–24 However, 
tobacco and alcohol consumption, which are the major 
risk factors for oesophageal squamous cell carcinoma in 
many parts of the world, are not strong risk factors in the 
Asian oesophageal cancer belt.22,23,25,26 Case-control and 
cohort studies have found that opium use, consumption 
of hot tea, low intake of fresh fruits and vegetables, 
indoor air pollution, exposure to polycyclic aromatic 
hydrocarbons, lack of access to piped water, poor oral 
health, and low socioeconomic status are also associated 
with a higher risk of oesophageal squamous cell 
carcinoma.26–32 However, as yet, no single dominant risk 
factor has been identified for oesophageal squamous cell 
carcinoma in the Asian oesophageal cancer belt. Most 
published findings of risk factors for oesophageal cancer 
in the Asian oesophageal cancer belt come from studies 
done in China and Iran. No recent studies have been 
done in Mongolia to address the high incidence and 
mortality rates in this population, although several risk 
factors are shared with other high-risk areas, such as 
high level of fluoride in drinking water or drinking hot 
milk tea.33 High rates of oesophageal cancer in eastern, 
central, and southern sub-Saharan Africa, an area dubbed 
the African oesophageal cancer corridor, are also well 
established.34 The majority of cases in this area are also 
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oesophageal squamous cell carcinoma. Until recently, 
few studies had been done to identify risk factors for 
oesophageal cancer in this region. Recent studies, 
however, have suggested that tobacco use,35 alcohol 
consumption,35,36 dental fluorosis,34 consumption of hot 
beverages,36 and exposure to biomass smoke37,38 are risk 
factors. Case-control studies have been completed or are 
ongoing in several countries in this region, including 
Kenya, South Africa, Malawi, Uganda, Tanzania, and 
Zambia, and further results are expected to be published 
within the next few years.
Although GBD estimates show major variations in age-
standardised incidence, mortality, and DALYs across 
regions and countries, there might be finer variations 
within countries not captured by these data. A prominent 
epidemiological feature of oesophageal squamous cell 
carcinoma, which constitutes the majority of oesophageal 
cancer cases worldwide, is that, for unknown reasons, 
rates of this disease can change sharply over relatively 
short distances. Therefore, countries marked as medium 
risk or low risk might have areas with a very high risk of 
oesophageal squamous cell carcinoma. For example, 
although Iran is not marked as a high-risk country for 
oesophageal cancer, Golestan Province in the northern 
part of Iran, bordering Turkmenistan, has some of the 
highest rates of oesophageal squamous cell carcinoma in 
the world.21,39 Likewise, although India and Brazil are not 
considered to be high-risk countries, certain areas of these 
countries (eg, the Kashmir Valley in India and Rio Grande 
do Sul in Brazil) have high rates of oesophageal cancer.20,40,41 
Such stark differences in incidence over short distances 
could lead to erroneous results when spatiotemporal 
smoothing methods are used. A country with no data and 
low incidence rates might be considered a high-incidence 
country if it has a neighbouring country with high 
incidence rates. Therefore, more granular geographical 
data need to be collected.3
Although there was a global decrease in age-standardised 
incidence rates of oesophageal cancer between 1990 
and 2017, the age-standardised rates increased in several 
countries, particularly in high-income countries. This is 
likely to be because the rates of oesophageal adeno-
carcinoma (but not oesophageal squamous cell carcinoma) 
have increased in high-income countries (eg, the USA, 
Germany, and the Netherlands) since the 1990s.5,8 The two 
main histological subtypes of oesophageal cancer, 
oesophageal squamous cell carcinoma and oesophageal 
adenocarcinoma, have very distinct risk factors, incidence 
trends, and geographical distributions.22 For example, 
although alcohol consumption is a major risk factor for 
oesophageal squamous cell carcinoma, it is not a risk 
factor for oesophageal adenocarcinoma.42,43 Conversely, 
although obesity and gastro-oesophageal reflux are major 
risk factors for oesophageal adenocarcinoma,44,45 they are 
not risk factors for oesophageal squamous cell carcinoma. 
Thus, although we observed an overall decline in the age-
standardised rates of oesophageal cancer, the picture is 
different for oesophageal squamous cell carcinoma and 
oesophageal adenocarcinoma. The age-adjusted incidence 
rates of oesophageal cancer increased in a minority 
of oesophageal squamous cell carcinoma-dominant 
countries, particularly in countries in sub-Saharan Africa 
(eg, Chad, Benin, and Sierra Leone), which could be due to 
improvements in cancer registry systems in this region.
This study found tobacco smoking, tobacco chewing, 
alcohol consumption, low intake of fruit, and high BMI 
to be important oesophageal cancer risk factors, 
accounting for most of the burden. Of these factors, high 
BMI is an established risk factor for oesophageal 
adenocarcinoma but has no proven association with 
oesophageal squamous cell carcinoma risk. Given the 
poor survival rate of patients with oesophageal cancer, 
major efforts to reduce these risk factors should be 
undertaken, particularly given that many oesophageal 
cancer risk factors (eg, smoking and obesity) are also 
important risk factors for other major chronic diseases, 
such as cardiovascular diseases and other cancers.
Although there were some exceptions, we found an 
overall inverse association between the age-standardised 
incidence of oesophageal cancer and SDI at the country 
level. These findings are consistent with previous 
epidemiological studies that have shown an inverse 
association between oesophageal squamous cell 
carcinoma and socioeconomic status.22,27,30,46,47 Despite 
recent rises in the age-standardised incidence rates of 
oesophageal adenocarcinoma, oesophageal squamous 
cell carcinoma still constitutes the majority of global 
oesophageal cancer cases. Therefore, on a global basis, 
an inverse association between oesophageal cancer and 
SDI is expected. It has been argued that substantial 
decreases in the rate of oesophageal squamous cell 
carcinoma in some of parts of the world might be due to 
improved socioeconomic status.48 Low SDI is a proxy for 
multiple correlated and interconnected variables such as 
unimproved water sources and high indoor air pollution. 
Indeed, recent studies have suggested that exposure to 
biomass smoke and indoor air pollution, lack of access to 
piped water, poor oral health, opium consum ption, and 
consumption of very hot drinks are risk factors for 
oesophageal squamous cell carcinoma.27,32,36
The poor prognosis of oesophageal cancer, indicated by 
the high MIR, might also call for screening efforts in the 
general population or in high-risk groups. Early detection 
of oesophageal cancer is also appealing because 
premalignant lesions and early cancers can now be 
treated with methods that are less invasive than surgery, 
such as endoscopic mucosal resection and endoscopic 
submucosal dissection, photodynamic therapy, argon 
plasma coagulation, radiofrequency ablation, and 
cryotherapy.49,50 In some areas of China that have high 
incidence rates of oesophageal squamous cell carcinoma 
and its precursor lesions (ie, squamous dysplasia), mass 
upper gastrointestinal endoscopy has been shown to 
increase survival51 and to be highly cost-effective.52 
Articles
592 www.thelancet.com/gastrohep   Vol 5   June 2020
However, in most other parts of the world, the prevalence 
rates of these precursor lesions are too low, even among 
cigarette smokers and alcohol drinkers, to merit upper 
gastrointestinal endoscopy and potentially invasive 
treatment. Other screening methods, such as cytological 
detection of dysplasia by use of balloon samplers, have 
shown low sensitivity and specificity for precursor lesions 
of oesophageal squamous cell carcinoma,53 resulting in 
high false positive and false negative rates. Due to its low 
prevalence and low progression rates, screening for 
oesophageal adenocarcinoma via its precursor lesion 
(Barrett’s oesophagus) is not cost-effective.54 Early 
detection of oesophageal cancer might also occur as a 
byproduct of screening for gastric cancer. For example, in 
South Korea, mass screening for gastric cancer by use of 
upper endoscopy or upper gastrointestinal series, which 
is done as part of a national screening programme,55 
might also help in early detection of oesophageal cancer. 
In some parts of the world, such as in China, incidence 
rates of both oesophageal cancer and gastric cancer are 
high, and mass endoscopic screening efforts might be 
beneficial to detect both cancers at early stages.56
Primary prevention of oesophageal cancer with 
chemopreventive measures has been the subject of many 
observational studies and randomised trials.57,58 Long-
term use of aspirin and other non-steroidal anti-
inflammatory drugs, statins, and anti-reflux therapy have 
been suggested to reduce the risk of oesophageal 
adenocarcinoma,57 whereas supplemental selenium and 
other micronutrients might reduce the risk of 
oesophageal squamous cell carcinoma.58,59 However, the 
level of evidence is not high enough to suggest 
widespread use of any of these drugs for primary 
prevention of oesophageal squamous cell carcinoma or 
oesophageal adenocarcinoma.59 The use of statins, 
however, has been growing over the past few decades, 
primarily because of their cardioprotective effects.
Presenting data from 195 countries and territories over 
three decades, this study is, to our knowledge, the most 
comprehensive and up-to-date analysis of the global 
burden, trends, and risk factors of oesophageal cancer. 
Linking data to Cancer Incidence in Five Continents 
provided, we believe for the first time, an opportunity to 
investigate associations with several potential risk 
factors of oesophageal squamous cell carcinoma at the 
country level. The data and findings, however, have 
several limitations. The two main histological subtypes 
of oesophageal cancer, oesophageal squamous cell 
carcinoma and oesophageal adenocarcinoma, have 
distinct risk factors, incidence trends, and geographical 
distributions,22 but data for these two subtypes are not 
currently captured independently in GBD. We suggest 
collection of data by histological subtype, where possible. 
By linking the GBD estimates to Cancer Incidence in 
Five Continents, we were able to find a partial solution to 
this limitation. As with other GBD cancer data, some 
countries did not have complete mortality or incidence 
data, and hence estimates were obtained by use of 
modelling. This modelling could be more problematic 
for oesophageal cancer than for other cancers, as rates of 
oesophageal squamous cell carcin oma might be 
drastically different across relatively short geographical 
distances. There is growing evidence that consumption 
of very hot drinks is a risk factor for oesophageal 
squamous cell carcinoma, particularly in very high-risk 
areas of the world, but GBD did not have data on this 
variable.
In conclusion, despite reductions in age-standardised 
incidence and mortality rates, oesophageal cancer 
remains a major cause of cancer mortality and burden 
across the world. The bulk of the burden of oesophageal 
cancer comes from east Asia, particularly from China. 
Areas with the highest age-standardised incidence, 
mortality, and DALY rates are located in east and central 
Asia and eastern, central, and southern sub-Saharan 
Africa. Although the exact reasons for these high rates 
are unclear, many epidemiological studies are ongoing, 
and we expect to see new findings over the next few 
years. In the meantime, intensive reduction of major 
known and potential oesophageal squamous cell 
carcinoma risk factors (primarily tobacco use, alcohol 
consumption, indoor air pollution, and consumption of 
very hot drinks) and oesophageal adenocarcinoma 
(primarily obesity and tobacco use) are strongly 
recommended. Where possible, it would be useful to 
collect country-level data on other risk factors such as 
consumption of opium and hot drinks, and water pipes 
(eg, hookahs). It would also be advisable to collect data 
on the histology of oesophageal cancer, and to treat 
oesophageal squamous cell carcinoma and oesophageal 
adeno carcinoma as two distinct entities for future 
analyses. High mortality-to-incidence ratios highlight 
the importance of primary and secondary prevention. 
Screening might be advised only in certain geographical 
areas with a very high risk of oesophageal squamous cell 
carcinoma and high prevalence of squamous dysplasia. 
Further development of less invasive screening methods 
should be highly encouraged.
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